Dr. Porter is the Jodi Fisher-Horowitz Professor of Leukemia Care Excellence at the Perelman School of Medicine and Abramson Cancer Center, and Director of Blood and Marrow Transplantation at the Hospital of the University of Pennsylvania.
He is a graduate of the University of Rochester and earned a medical degree at Brown University. He completed internship and residency at Boston University Hospital, and fellowship training at Brigham and Women’s Hospital and Harvard Medical School in Boston.
He chairpersons or serves on multiple local, national and international committees focused on hematologic malignancies and SCT and is a member of the Board of Directors of the National Marrow Donor Program. Dr Porter is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the American Society of Blood and Marrow Transplantation. He has authored more than 120 research articles and book chapters, is an Associate Editor for the American Journal of Hematology and has served as a manuscript reviewer for numerous medical journals, including Blood, Annals of Internal Medicine and The New England Journal of Medicine. He is annually recognized as a “Top Doc” in Philadelphia Magazine and in 2007 was the recipient of the Leukemia and Lymphoma Society Service to Mankind Award, bestowed for “dedicated service to the highest standards of the medical profession, his humanistic approach to patient care, and his tireless efforts in researching cures for blood cancers”.
Dr. Porter has expertise in the care of patients with hematologic malignancies, and in all aspects of autologous and allogeneic SCT and leads numerous local and national research activities. He is an accomplished clinical investigator and has published extensively in the field of stem cell transplantation and hematologic malignancies. His principal research interests are in development of novel methods of cellular therapy, stem cell transplantation and allogeneic adoptive immunotherapy. Recent research highlights include the successful use of genetically modified T cells to treat CLL and ALL, novel trials designed to prevent GVHD after allogeneic SCT by blocking lymphocyte trafficking, and studies to enhance graft-vs-tumor activity after SCT.